Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Assures Investors: “Right Moment Is Now” To Acquire Genentech

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche would consider another Genentech-like deal, but the biotech itself has grown too large and the time is right to bring it in-house, Humer says.

You may also be interested in...

Roche Keeps Shopping: Mirus Acquisition Bolsters RNAi Portfolio

Firm will pay $125 million for access to Wisconsin-based Mirus’ Dynamic PolyConjugates technology.

Genentech/Roche: The End Of An Era

Roche offers to buy out Genentech’s minority stakeholders for $89 per share, or $43.7 billion, to create the seventh largest U.S. pharma company.

MedImmune’s CEO Stepping Down

AstraZeneca’s North American CEO Zook will assume responsibilities until a successor is hired.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts